Drug intelligence / Profile preview

IMC-4022

Development stage: Preclinical
Lead developer: ImmuneCyte Life Sciences
Modality: Cell Therapies
Administration: Intravenous

Overview

IMC-4022 is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy developed by ImmuneCyte Life Sciences using its proprietary AutoTIL platform. The therapy involves the isolation of naturally occurring T cells from a patient's tumor, followed by ex vivo expansion and re-infusion into the patient to enhance the immune response against malignant cells. IMC-4022 is specifically being investigated for the treatment of Renal Cell Carcinoma (RCC) and is currently in the preclinical/pilot stage of development.

Beyond the preview

Go deeper on IMC-4022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC-4022.

Explore the full profile